vindesine sulphate

CLINICAL USE

Antineoplastic agent

DOSE IN NORMAL RENAL FUNCTION

3–4 mg/m2 weekly

PHARMACOKINETICS

Molecular weight : 852

%Protein binding : No data

%Excreted unchanged in urine : 13

Volume of distribution (L/kg) : 8

half-life – normal/ESRD (hrs) : 20–24

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unlikely to be dialysed. Dose as in normal renal function

HD : Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux : Unknown dialysability. Dose as in normal renal function

CAV/VVHD : Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

5 mL sodium chloride 0.9% per 5 mg vial

Route

Rate of Administration

1–3 minutes

Comments

Can be injected into the tubing of a fast running infusion of sodium chloride 0.9%, glucose 5% or glucose/saline solutions, or directly into a vein Reconstituted solution is stable for 24 hours if stored in a fridge

OTHER INFORMATION

Nadir of the WCC occurs 3–5 days after dose with recovery after another 4–5 days Metabolised by cytochrome P450 (in the CYP 3A subfamily). Elimination is primarily biliary (13% excreted in urine in 24 hrs) Vindesine sulphate .

Tags: post-by-auto-php